NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis $5.04 -0.01 (-0.10%) As of 01:01 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vanda Pharmaceuticals Stock (NASDAQ:VNDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vanda Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.97▼$5.0550-Day Range$4.93▼$5.5752-Week Range$4.27▼$9.94Volume243,307 shsAverage Volume1.52 million shsMarket Capitalization$305.02 millionP/E RatioN/ADividend YieldN/APrice Target$13.08Consensus RatingModerate Buy Company Overview Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for disorders involving the central nervous system and circadian rhythm. Founded in 2003 and headquartered in Washington, D.C., the company conducts clinical development, regulatory, and commercial activities primarily in the United States, with efforts to make its products available in additional markets where approved. Vanda’s marketed products include Hetlioz (tasimelteon), a melatonin-receptor agonist approved for the treatment of Non-24-Hour Sleep-Wake Disorder in adults who are totally blind and for nighttime sleep disturbances in certain patients with Smith-Magenis syndrome. The company also markets Fanapt (iloperidone), an atypical antipsychotic approved for the treatment of schizophrenia in adults. In addition to its commercial products, Vanda has pursued clinical programs in areas including gastrointestinal and neurological disorders. Its investigational therapies have included tradipitant, which has been studied for conditions such as gastroparesis and motion sickness. Vanda was founded and has been led by Mihael H. Polymeropoulos, who serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Vanda Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreVNDA MarketRank™: Vanda Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 401st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingVanda Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialVanda Pharmaceuticals has a consensus price target of $13.08, representing about 161.4% upside from its current price of $5.01.Amount of Analyst CoverageVanda Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Vanda Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($3.02) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vanda Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.73% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 12.07, which indicates bearish sentiment.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 10.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.15 News SentimentVanda Pharmaceuticals has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Vanda Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.70% of the stock of Vanda Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VNDA Stock News HeadlinesVanda's Year-End Catalysts: Three Phase 3 Readouts And An FDA Decision Ahead2 hours ago | rttnews.comOppenheimer initiates coverage of Vanda Pharmaceuticals with an outperform ratingSeptember 23, 2026 | msn.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 28 at 1:00 AM | Porter & Company (Ad)Vanda Pharmaceuticals Announces Participation at September 2026 Investor ConferencesSeptember 2, 2026 | prnewswire.comVanda Pharmaceuticals Inc. (VNDA)August 25, 2026 | finance.yahoo.comVanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European CommissionAugust 24, 2026 | prnewswire.comNEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.August 22, 2026 | prnewswire.comVanda (VNDA) Q2 2026 Earnings Call TranscriptAugust 12, 2026 | finance.yahoo.comSee More Headlines VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed this year? Vanda Pharmaceuticals' stock was trading at $8.82 at the beginning of 2026. Since then, VNDA stock has decreased by 43.3% and is now trading at $5.0050. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.46. The biopharmaceutical company had revenue of $50.53 million for the quarter, compared to the consensus estimate of $61.93 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative trailing twelve-month return on equity of 49.81%. Read the conference call transcript. Who are Vanda Pharmaceuticals' major shareholders? Top institutional investors of Vanda Pharmaceuticals include BlackRock Inc. (12.73%), State Street Corp (5.82%), AIGH Capital Management LLC (3.40%) and Ieq Capital LLC (0.47%). Insiders that own company stock include Mihael Hristos Polymeropoulos, Gunther Birznieks, Kevin Patrick Moran, Timothy Williams, Joakim Wijkstrom and Stephen Ray Mitchell. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/05/2026Today9/28/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VNDA's financial health is in the Red zone, according to TradeSmith. VNDA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VNDA CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees533Year Founded2002Price Target and Rating Average Price Target for Vanda Pharmaceuticals$13.08 High Price Target$20.00 Low Price Target$7.50 Potential Upside/Downside+159.3%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$220.47 million Net Margins-127.41% Pretax Margin-82.14% Return on Equity-49.81% Return on Assets-33.29% Debt Debt-to-Equity Ratio0.01 Current Ratio1.61 Quick Ratio1.60 Sales & Book Value Annual Sales$216.10 million Price / Sales1.41 Cash FlowN/A Price / Cash FlowN/A Book Value$5.54 per share Price / Book0.91Miscellaneous Outstanding Shares60,460,000Free Float53,993,000Market Cap$305.02 million OptionableOptionable Beta0.64 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:VNDA) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredHOST Just Closed Its Major Merger!Host Digital Inc (NYSE American: HOST) completed its merger with Healthy Choice Wellness Corp on September 17,...Trading Wire | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VNDA Stock Alerts